Transaction #33945 · Form 4 · 0001178579-26-000019

Boundless Bio, Inc. · Purchase · Common Stock

Boundless Bio, Inc. · Transacted October 19, 2026 · Filed October 20, 2026

Original SEC filing ↗

What does this filing report?

An SEC Form 4 filing for Boundless Bio, Inc. records a purchase involving Common Stock on October 19, 2026. The reported quantity was 12,790. The filing date is October 20, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Transaction details

Company CIK
0001782303
Security type
Non-derivative
Acquisition type
Purchase · Code P
Quantity acquired
12,790
Reported price
2.34 · See footnotes
Reference value
29,928.6
Currency
Currency not specified
Ownership
Indirect
Holdings after transaction
2,971,610
Ownership description
See Footnote
SEC acceptance time
Oct 20, 2026, 5:49 PM EDT
10b5-1 indication
Not indicated

Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.

Reporting owners

These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.

Company listings

BOLD · Nasdaq · linked security

The linked listing is identified separately from other current company listings.

Filing footnotes & remarks

F1
The Reporting Persons have delivered to the Issuer the full amount of the disgorgeable profit arising the purchases reported herein, in the amount of $1,723.10.
F2
The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $2.31 to $2.35. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the range set forth in Footnotes 2 and 4 through 6.
F3
Tang Capital Partners, LP ("TCP") beneficially owns 688,494 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 937,213 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 688,487 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 675,915 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
F4
These shares were purchased in multiple transactions at prices ranging from $2.31 to $2.35.
F5
These shares were purchased in multiple transactions at prices ranging from $2.32 to $2.35.
F6
These shares were purchased in multiple transactions at prices ranging from $2.33 to $2.40.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.

This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.